糖尿病患者从门诊到住院继续使用SGLT2抑制剂与住院结局的关联:一项全国性队列研究
该全国性队列研究纳入36505例住院前门诊有SGLT2抑制剂处方的糖尿病患者,比较住院期间继续与停用SGLT2抑制剂的结局。继续组院内死亡风险降低45%(IRR 0.55,95%CI 0.42-0.73,P<0.01),急性肾损伤无差异(IRR 0.96,95%CI 0.90-1.02,P=0.17),住院时间缩短(4.7 vs 4.9天;IRR 0.95,95%CI 0.93-0.98,P<0.01)。
要点
- 住院期间继续使用SGLT2抑制剂与较低的院内死亡风险相关(IRR 0.55)。
- 继续使用SGLT2抑制剂与急性肾损伤风险无显著差异(IRR 0.96)。
- 继续使用SGLT2抑制剂与住院时间缩短相关(4.7 vs 4.9天)。
核心结论
- 糖尿病患者住院期间继续使用SGLT2抑制剂与较低的死亡率、未增加的急性肾损伤及较短的住院时间相关。
研究设计与样本
- 全国性队列研究,使用退伍军人事务医疗系统2013年4月1日至2021年8月31日期间的急性住院数据。
- 共纳入36505例住院前门诊有SGLT2抑制剂处方的糖尿病患者的住院记录。
- 暴露为住院期间继续使用SGLT2抑制剂,与停用者进行比较。
- 采用负二项倾向评分加权和零截断分析,并调整人口学特征和合并症等多重协变量。
主要发现
- 继续组与停用组的平均(SE)年龄分别为67.2(0.1)岁和67.5(0.1)岁(P=0.03),男性分别占97.0%和96.6%(P=0.1),白人分别占71.3%和72.1%,黑人分别占20.8%和20.5%(P=0.52)。
- 调整协变量(年龄、性别、种族、BMI、Elixhauser合并症指数、手术/操作及胰岛素使用)后,继续组较停用组的死亡风险降低45%(IRR 0.55,95%CI 0.42-0.73,P<0.01)。
- 继续组与停用组的急性肾损伤无差异(IRR 0.96,95%CI 0.90-1.02,P=0.17)。
- 继续组较停用组的住院时间缩短(4.7 vs 4.9天;IRR 0.95,95%CI 0.93-0.98,P<0.01)。
- 多项敏感性分析观察到相似的关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Limited data are available on the continuation of outpatient sodium glucose cotransporter 2 inhibitors (SGLT2is) during hospitalization. The objective was to evaluate associations of SGLT2i continuation in the inpatient setting with hospital outcomes. RESEARCH DESIGN AND METHODS: This nationwide cohort study used Veterans Affairs health care system data of acute care hospitalizations between 1 April 2013 and 31 August 2021. A total of 36,505 admissions of patients with diabetes with an outpatient prescription for an SGLT2i prior to hospitalization were included. The exposure was defined as SGLT2i continuation during hospitalization. Admissions where SGLT2i was continued were compared with admissions where it was discontinued. The primary outcome was in-hospital mortality. Secondary outcomes were acute kidney injury (AKI) and length of stay (LOS). Negative binomial propensity score-weighted and zero-truncated analyses were used to compare outcomes and adjusted for multiple covariates, including demographics and comorbidities. RESULTS: Mean (SE) age was 67.2 (0.1) and 67.5 (0.1) years (P = 0.03), 97.0% and 96.6% were male (P = 0.1), 71.3% and 72.1% were White, and 20.8% and 20.5% were Black (P = 0.52) for the SGLT2i continued and discontinued groups, respectively. After adjustment for covariates (age, sex, race, BMI, Elixhauser comorbidity index, procedures/surgeries, and insulin use), the SGLT2i continued group had a 45% lower mortality rate (incidence rate ratio [IRR] 0.55, 95% CI 0.42-0.73, P < 0.01), no difference in AKI (IRR 0.96, 95% CI 0.90-1.02, P = 0.17), and decreased LOS (4.7 vs. 4.9 days) (IRR 0.95, 95% CI 0.93-0.98, P < 0.01) versus the SGLT2i discontinued group. Similar associations were observed across multiple sensitivity analyses. CONCLUSIONS: Continued SGLT2i during hospitalization among patients with diabetes was associated with lower mortality, no increased AKI, and shorter LOS.
引用
- Singh LG, Ntelis S, Siddiqui T, et al. Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study. Diabetes Care. 2024. PMID: 38051789. doi:10.2337/dc23-1129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。